Abeona Therapeutics (ABEO) director reports bona fide 500-share gift

Rhea-AI Filing Summary

Abeona Therapeutics director Mark Alvino reported a bona fide gift of 500 shares of Common Stock. The gift was recorded at a price of $0.00 per share, reflecting a non-market, no‑consideration transfer. Following this disposition, he directly holds 77,065 shares of Abeona Therapeutics common stock.

Insider Trade Summary

500 shares gifted

Mixed 1 txn

Insider Alvino Mark

Role null

Type	Security	Shares	Price	Value
Gift	Common Stock	500	$0.00	--

Holdings After Transaction: Common Stock — 77,065 shares (Direct, null)

Footnotes (1)

Key Figures

Gifted shares: 500 shares Gift price per share: $0.00 per share Shares after transaction: 77,065 shares +1 more

4 metrics

Gifted shares 500 shares Bona fide gift of common stock on Form 4

Gift price per share $0.00 per share Reported value for the 500-share gift

Shares after transaction 77,065 shares Direct holdings following the gift disposition

Transaction code Code G (bona fide gift) Non-derivative disposition classification

Key Terms

bona fide gift, Common Stock, Form 4

3 terms

bona fide gift financial

"transaction_code_description: "Bona fide gift""

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alvino Mark

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		G		500	D	$0	77,065	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Mark Alvino	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Abeona Therapeutics (ABEO) director Mark Alvino report?

Director Mark Alvino reported a bona fide gift of 500 shares of Abeona Therapeutics common stock. The transaction was coded as a gift (Code G) and recorded at a per‑share price of $0.00, indicating no sale proceeds or market trade.

How many Abeona Therapeutics (ABEO) shares does Mark Alvino hold after this Form 4?

After the reported gift of 500 shares, Mark Alvino directly holds 77,065 shares of Abeona Therapeutics common stock. This figure reflects his direct ownership position immediately following the transaction disclosed in the Form 4 filing.

Was the Abeona Therapeutics (ABEO) insider transaction a market sale or purchase?

The transaction was not a market sale or purchase; it was a bona fide gift of 500 shares. The Form 4 lists a transaction price of $0.00 per share, confirming that no cash consideration changed hands in this disposition.

How is the Abeona Therapeutics (ABEO) insider transaction classified on the Form 4?

The transaction is classified as a non‑derivative disposition with code G, described as a bona fide gift. It involves 500 shares of common stock and is treated as a gift transfer rather than a typical open‑market trading activity.

Does the Form 4 for Abeona Therapeutics (ABEO) show any option exercises or derivative trades?

The Form 4 data shows no derivative transactions or option exercises. The derivativeSummary is empty, and the transactionSummary reports zero derivative transactions, indicating only the reported 500‑share gift of common stock occurred in this filing.